20/04 L1 Group fait le point sur l'introduction en bourse de L1 Gold Fund Limited RE 20/04 L1 Group annonce que l'IPO de L1 Gold Fund a généré 950 millions de dollars australiens MT 14/04 L1 Group ...
14/04 L1 Group fait état de 16 963 millions de dollars australiens d'actifs sous gestion au 31 mars RE 14/04 L1 Group fait état d'une baisse de ses actifs sous gestion au premier trimestre MT 26/03 L1 ...
Jiangsu Hengrui Pharma has chalked up a first-in-class approval for retlirafusp alfa, a bifunctional drug that targets PD-L1 and TGF-beta, as a treatment for advanced gastric cancer. The green light – ...
Mark Landau, the co-chief investment officer at L1 Capital, uses an example every Australian investor can understand to explain why he and his partner Raphael Lamm see much more exciting opportunities ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results